12:00 AM
Apr 23, 2012
 |  BioCentury  |  Emerging Company Profile

ProLynx: Hitting the links

ProLynx's linker technology releases drugs at pre-programmed rates

ProLynx LLC has developed conjugate linkers that increase a drug's duration of action by releasing active therapeutics at consistent, preprogrammed rates. By doing so, the company thinks it can overcome the drawbacks of other conjugate technologies.

First-generation conjugates increase duration of action by covalently attaching active drug to a macromolecular carrier, such as PEG or serum albumin. But these bound carriers often reduce a drug's biological activity and preclude intracellular action, according to ProLynx co-founder and President Daniel Santi.

Second-generation technologies typically use linkers that are cleaved by esterases, releasing the drug to act unencumbered by the carrier. However, Santi said, ester-containing linkers have a maximum half-life of one or two days, which limits their ability to continuously keep the drug...

Read the full 593 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >